Nephrology

Change in albuminuria as a surrogate endpoint for progression of chronic kidney disease strongly supported by biological plausibility, but empirical evidence to support validity in epidemiological studies still lacking.

Researchers develop way to measure abundance of 12 different complement proteins in the urine.

FDA label change warns of increased risk of lactic acidosis in patients with severe renal dysfunction.

Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.

Elevated eGR fund to possibly lead to renal damage.

Drug shown to reduce risk of CV death or hospitalization for heart failure in adults with CV disease and type 2 diabetes, irrespective of their CV risk at study start.

In results of five trials, effects of antihyperglycemic drug found to occur during first few months or years.

Individuals with undiagnosed diabetes, prediabetes found to have high incidence of unrecognized chronic kidney disease.

Mortality rates increased in adults with diabetes, low estimated glomerular filtration rate in absence of albuminuria.

Study confirms recent guideline changes on metformin use in moderate-to-severe chronic kidney disease.